Financial Data and Key Metrics Changes - The company ended Q1 with a negative growth of 1%, but excluding two large cell therapy customers, the growth for the rest of the business was approximately 1% [6][8] - The company anticipates a similar overall growth rate for Q2, projecting a decline of about 1% but an improvement to 3% when excluding the impact of the two customers [25][30] Business Line Data and Key Metrics Changes - The diagnostics business grew mid-single digits in Q1, building on a mid-teen growth from the previous year, indicating a strong performance despite fluctuations [30] - The ProteinSimple franchise has consistently outperformed, with no down quarters and double-digit growth in recent periods, suggesting resilience in a challenging market [26][70] - The Spatial Biology segment experienced a flat performance in Q1 after a down quarter, but bookings increased double-digit, indicating potential for recovery [27][75] Market Data and Key Metrics Changes - The pharmaceutical market, which constitutes 30% of revenue, has shown recovery with double-digit growth in recent quarters, alleviating previous concerns about regulatory pressures [12][13] - Academic market conditions have stabilized, with expectations of a flat NIH budget, improving sentiment among academic customers [14][66] - Biotech funding has improved, with funding levels increasing from a decline of 30% to a decline of 13%, suggesting a potential recovery in spending [17][22] Company Strategy and Development Direction - The company is focusing on its ProteinSimple and Spatial franchises to drive growth, especially as market conditions stabilize [26][75] - The strategy includes leveraging the strong demand for consumables and reagents associated with their instruments, which are expected to enhance margins over time [77][80] - The company is optimistic about the long-term potential of its cell therapy business, despite short-term challenges, due to the high quality of clinical trials being conducted [92][94] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism about the near-term outlook, noting that while challenges remain, there are signs of stabilization in key markets [12][14] - The company anticipates that improvements in funding and market conditions will begin to reflect in financial results by the second half of fiscal year 2026 [22][58] - Management highlighted the importance of maintaining strong relationships with customers and adapting to their needs as market conditions evolve [43][59] Other Important Information - The two large customers in the cell therapy space accounted for as much as 35%-40% of GMP revenue at their peak, but their absence is expected to impact revenue significantly in the near term [41][90] - The company has a diverse customer base, with 698 other customers, and is actively seeking to expand its reach in the cell therapy market through grant programs [94][96] Q&A Session Summary Question: What is the impact of the two large customers on revenue? - The two customers have significantly influenced revenue, making up a large portion of GMP revenue, and their absence is expected to reduce business temporarily [41][90] Question: How does the company view the recovery in the biotech market? - The company sees a lag of 2-3 quarters before funding translates into spending, but is optimistic about a recovery in fiscal year 2027 [58] Question: What are the expectations for the diagnostics business? - The diagnostics business is expected to continue performing well, with a more even revenue stream anticipated throughout the year [30][31] Question: How is the company addressing margin progression? - Management expects margin expansion to be consistent with revenue growth, projecting at least a 100 basis point improvement for the year [97]

Bio-Techne (NasdaqGS:TECH) FY Conference December 02, 2025 08:20 AM ET Company ParticipantsDaniel Markowitz - Equity Research AssociateChuck Kummeth - CEOJames Hippel - CFOJames HippelThank you both for being with us.Chuck KummethYeah, James, thanks for having us. Especially first thing after the turkey hangover.Daniel MarkowitzTurkey hangover. Starting off sort of high level on the one Q overview, you posted an organic decline of 1%. Can you just give us a quick overview of the quarter and, I guess, the ma ...

Financial Data and Key Metrics Changes - Quanterix reported total revenue of $40.2 million for Q3 2025, representing a 12% year-over-year increase [11] - The company ended the quarter with $138 million in cash, cash equivalents, marketable securities, and restricted cash [14][16] - Adjusted EBITDA was a loss of $11.9 million, compared to a loss of $5.5 million in the same quarter of the previous year [14] Business Line Data and Key Metrics Changes - Simoa contributed $23 million in revenue, reflecting a 36% organic revenue decline, while Spatial reported $17.2 million, down 9% year over year [11] - Consumable revenue totaled $18.8 million, with $12.3 million from Simoa and $6.5 million from Spatial [12] - Accelerator Lab revenue was $8 million, with $5 million from Simoa and $3 million from Spatial, showing a sequential increase of $1 million [12] Market Data and Key Metrics Changes - U.S. academic revenue declined approximately 30%, tracking the decline in academic grants, while pharma revenue declined 23% year over year [12] - Demand across the broader industry remains uneven, but signs of stabilization are noted, particularly in academic, government, and pharma markets [6] Company Strategy and Development Direction - The company is focused on integrating operations following the acquisition of Akoya, having realized $67 million of the targeted $85 million in synergies [5][8] - Significant investments are being made in Alzheimer's diagnostics and new assays across Simoa Spatial franchises, with approximately $27 million invested in R&D year to date [6][9] - The integration of Simoa and Spatial is expected to unlock new growth avenues, particularly in oncology and multimodal biomarker strategies [7][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving cash flow breakeven in 2026 and expects to finish the year with around $120 million in cash and no debt [6][9] - The company anticipates continued improvement in the operating environment, with a focus on capturing synergies and enhancing profitability [10][16] - Management remains cautious about the impact of the government shutdown on Q4 guidance, but believes risks have bottomed out [40] Other Important Information - The company is preparing for the launch of an early access program for Simoa ONE, which is expected to be a catalyst for future instrument growth in Alzheimer's diagnostics [9][67] - Diagnostics-related revenue was $2.4 million in the quarter, with expectations for stronger traction in 2026 based on established pricing recommendations [9][50] Q&A Session Summary Question: What is the outlook for Simoa consumables given the decline? - Management noted that while order volume was consistent, the order size was smaller due to a challenging academic grant environment, but expects smaller projects to scale in 2026 [20][22] Question: What are the plans for Q4 regarding integration and synergies? - Management confirmed that a single manufacturing team has been implemented and lab services are being combined, with expectations to capture remaining synergies in early 2026 [24][25] Question: How is the Akoya business expected to perform in Q4? - Management modeled a slight step down in Akoya's revenue for Q4 due to market uncertainty but noted strong execution in Q3 [28][29] Question: What is the competitive landscape and how is the company addressing it? - Management acknowledged competition in high sensitivity platforms but emphasized their unique position in the four to five marker space, which is expected to benefit from discovery progress [41][43] Question: What is the expected ramp-up for LucentAD in 2026? - Management indicated that established pricing will support stronger traction and growth in diagnostics revenue, with ongoing partnerships in Asia contributing positively [50][70]

Core Insights - 10x Genomics reported a revenue of $149 million for the quarter ended September 2025, reflecting a decrease of 1.8% year-over-year, while EPS improved to -$0.22 from -$0.30 in the previous year [1] - The revenue exceeded the Zacks Consensus Estimate of $142.39 million by 4.64%, and the EPS also surpassed the consensus estimate of -$0.27 by 18.52% [1] Revenue Breakdown - Services revenue was reported at $8.13 million, exceeding the average estimate of $7.86 million by analysts, marking a year-over-year increase of 27.1% [4] - Instruments revenue was $12 million, below the average estimate of $14.06 million, representing a significant decline of 37% year-over-year [4] - Chromium Instruments revenue was $4.93 million, slightly below the estimate of $5.36 million [4] - Consumables revenue from Chromium was reported at $92.52 million, surpassing the average estimate of $85.29 million [4] - Spatial Consumables revenue was $35.37 million, slightly above the average estimate of $35.06 million [4] - Total Consumables revenue reached $127.89 million, exceeding the average estimate of $120.35 million, with a year-over-year change of 1.3% [4] - Spatial Instruments revenue was reported at $7.07 million, below the average estimate of $8.71 million [4] Stock Performance - Over the past month, shares of 10x Genomics have returned +11.8%, significantly outperforming the Zacks S&P 500 composite, which saw a change of +1.3% [3] - The stock currently holds a Zacks Rank 1 (Strong Buy), indicating potential for outperformance in the near term [3]

Core Insights - 10x Genomics reported revenue of $172.91 million for the quarter ended June 2025, reflecting a year-over-year increase of 12.9% and surpassing the Zacks Consensus Estimate of $139.44 million by 24% [1] - The company achieved an EPS of $0.28, a significant improvement from -$0.32 in the same quarter last year, resulting in an EPS surprise of 180% compared to the consensus estimate of -$0.35 [1] Revenue Breakdown - Consumables revenue reached $122.19 million, slightly above the average estimate of $117.21 million, but showing a year-over-year decline of 1% [4] - Instruments revenue was reported at $14.5 million, below the average estimate of $14.9 million, marking a substantial year-over-year decrease of 39.2% [4] - Chromium instruments generated $5.73 million, slightly exceeding the estimated $5.6 million [4] - Services revenue amounted to $8.48 million, outperforming the estimate of $7.36 million, and reflecting a year-over-year increase of 43.9% [4] - Consumables from Chromium totaled $85.79 million, surpassing the estimate of $84.35 million [4] - Spatial consumables revenue was reported at $36.4 million, exceeding the average estimate of $32.86 million [4] - Spatial instruments revenue was $8.77 million, below the average estimate of $9.3 million [4] Stock Performance - Over the past month, shares of 10x Genomics have returned +4.6%, outperforming the Zacks S&P 500 composite's +1.2% change [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential for outperformance in the near term [3]

Core Insights - Niantic, known for the popular mobile game Pokémon GO, has decided to sell its gaming business for $3.5 billion to Scopely and shift its focus to enterprise-level AI, rebranding itself as Niantic Spatial [3][4][11] - The company aims to leverage its extensive location data, accumulated from players walking over 30 billion miles, to develop AI models that analyze the real world and serve enterprise clients [4][6][19] Group 1: Strategic Shift - The CEO John Hanke emphasized that the restructuring allows both the gaming and AI divisions to pursue their respective futures more effectively [4][11] - Niantic's new platform, Spatial, offers AI mapping tools for businesses, enabling applications such as robot route planning and augmented reality glasses [4][6] - The decision to pivot to AI reflects the broader impact of generative AI trends in Silicon Valley, with the spatial computing market projected to grow from $110 billion in 2023 to $1.7 trillion by 2033 [6][7] Group 2: Financial Aspects - Niantic raised $250 million from existing investors to fund the new company, with the transaction expected to complete by the end of the month [7] - The gaming business, particularly Pokémon GO, has generated approximately $8 billion in revenue since its launch in 2016, with an estimated $770 million contribution to Niantic's projected $1 billion revenue in 2024 [8][11] - Despite the sale, Niantic will continue to provide augmented reality mapping services to Scopely, maintaining access to critical location data for AI model development [20][21] Group 3: Competitive Landscape - Niantic faces strong competition in the spatial AI sector from companies like Nvidia, which has launched the Omniverse platform for creating 3D digital twins [7] - The company has also encountered challenges in replicating the success of Pokémon GO, with previous titles like Harry Potter: Wizards Unite failing to achieve similar popularity [10][16] Group 4: Data Privacy and Ethical Considerations - The sale of the gaming business raised concerns regarding user data management, particularly due to Scopely's backing by the Saudi sovereign wealth fund [21] - Hanke reassured that data privacy regulations will be strictly followed, and user data will remain under the control of Niantic and Scopely [21] - Niantic has clarified that data collection for AI model training will only occur with user consent during specific actions, addressing player concerns about data usage [21]

Core Insights - 10x Genomics reported revenue of $154.88 million for the quarter ended March 2025, reflecting a year-over-year increase of 9.8% and exceeding the Zacks Consensus Estimate of $133.25 million by 16.24% [1] - The company posted an EPS of -$0.36, an improvement from -$0.50 in the same quarter last year, with a surprise of 20.00% compared to the consensus estimate of -$0.45 [1] Revenue Breakdown - Consumables revenue reached $115.36 million, slightly below the average estimate of $115.85 million, marking a year-over-year increase of 4.6% [4] - Instruments revenue was reported at $14.82 million, significantly lower than the average estimate of $17.30 million, representing a year-over-year decline of 41.8% [4] - Chromium instruments generated $5.91 million, compared to the estimated $6.46 million [4] - Services revenue was $7.65 million, exceeding the average estimate of $6.30 million, with a year-over-year increase of 46.7% [4] - Consumables from Chromium totaled $84.11 million, surpassing the average estimate of $82.93 million [4] - Spatial consumables revenue was $31.25 million, slightly below the average estimate of $32.91 million [4] - Spatial instruments revenue was $8.90 million, compared to the estimated $10.85 million [4] Stock Performance - Over the past month, shares of 10x Genomics have declined by 4.2%, while the Zacks S&P 500 composite increased by 11.3% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]